CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
CSL has entered an exclusive global collaboration with Alentis Therapeutics to co-develop and co-promote lixudebart, a first-in-class anti-claudin-1 antibody, in AAV-RPGN, FSGS and primary sclerosing cholangitis. CSL will pay US$355 million upfront with Alentis eligible for up to US$1.2 billion in commercial milestones; CSL funds all development including the Phase 2 RENAL trial and planned Phase 3, with global profits split 55% CSL / 45% Alentis.
Key figures
- Drug Name
- lixudebart (formerly ALE.F02)
- Phase Of Trial
- Phase 2
- Profit split csl
- 55%
- Upfront payment usd
- 355000000
- Profit split alentis
- 45%
- Commercial milestones usd
- 1200000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.